Science and Discovery

Targeted Therapy

2 articles

Microscopic view of lung cancer cells being targeted by Pfizer's lorlatinib, illustrating a breakthrough in targeted cancer therapy and improved patient survival rates.
Cosmos & Space

Pfizer lung cancer drug: 60% progression-free after five years

After five years, 60% of patients with a specific type of lung cancer treated with Pfizer's lorlatinib were still alive without their disease progressing, a dramatic finding compared to just 8% on the

Marcus Cole·June 23, 2026
Medical researcher examining a glowing molecular model of Daraxonrasib, with hopeful patients in the background, symbolizing a breakthrough in pancreatic cancer treatment.
Health & Medicine

Daraxonrasib Doubles Survival in Pancreatic Cancer Treatment Trials

In a recent clinical trial, patients with advanced pancreatic cancer receiving Daraxonrasib lived more than twice as long as those on standard chemotherapy.

David Grossman·June 19, 2026